Literature DB >> 582251

Neuropathology of fatal varicella.

S Takashima, L E Becker.   

Abstract

Pathological examination of the CNS was carried out in the cases of 32 children who died of varicella. Twelve had acute encephalopathy with fatty degeneration of liver. Eighteen children had underlying disease; two thirds of them had received steroids. Two children had neonatal varicella. Only two brains of the total number of children had demonstrable inclusion bodies, and these were unique cases. One infant brain had focal encephalitis in an area of necrosis around a ventricular catheter, and the other, a case of neonatal varicella, had multiple disseminated necrotic foci. These observations suggest that true encephalitis is a rare event in fatal varicella.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582251

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

Review 1.  Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment.

Authors:  Don Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Lancet Neurol       Date:  2009-08       Impact factor: 44.182

2.  Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections.

Authors:  Anna Grahn; Lars Hagberg; Staffan Nilsson; Kaj Blennow; Henrik Zetterberg; Marie Studahl
Journal:  J Neurol       Date:  2013-03-08       Impact factor: 4.849

3.  Varicella-zoster virus-infected human sensory neurons are resistant to apoptosis, yet human foreskin fibroblasts are susceptible: evidence for a cell-type-specific apoptotic response.

Authors:  C Hood; A L Cunningham; B Slobedman; R A Boadle; A Abendroth
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 4.  Acute disseminated encephalomyelitis: clinical and pathogenesis features.

Authors:  Farshid Noorbakhsh; Richard T Johnson; Derek Emery; Christopher Power
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.